MUNICH, July 15, 2016 /PRNewswire/ --
Dr. Andreas Rummelt, pharma industry expert and former CEO of Sandoz, was elected as new supervisory board member at LEUKOCARE's annual shareholder meeting on July 12th
LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for biopharmaceuticals like biologics and vaccines, announces the election of Dr. Andreas Rummelt as new member of its supervisory board. Together with Dr. Jean-Paul Prieels, who held various executive positions at GlaxoSmithKline, former Sandoz CEO Dr. Rummelt is the second former executive from big pharma on the LEUKOCARE board.
Dr. Rummelt's international career included multiple executive positions within Sandoz and Novartis where he focused on the areas of manufacturing, quality, and technical development of pharmaceutical originals and generics. He has served more than twenty years in executive management positions in the industry. He joined Sandoz Pharma Ltd. in 1985 in Switzerland and was CEO of Sandoz, the Generics Division of Novartis, in Vienna, Austria and Holzkirchen, Germany from 2004 to 2008. Today, Dr. Rummelt is Managing Partner with InterPharmaLink, a Basel-based consulting firm to pharma, biotech, generics and other healthcare sectors. He holds various board seats in public and private companies, e.g. with Alexion Pharmaceuticals, Alvogen and Xellia Pharmaceuticals.
"We are very pleased that Dr. Rummelt is joining our supervisory board", said Michael Scholl, CEO of LEUKOCARE. "We are sure that his expertise and network in the industry will support our strategy to become an even stronger player in the field of pharmaceutical formulation development to offer outstanding solutions for biopharmaceutical products", he added.
"I am looking forward to supporting the company's further development and the roll out of the technology in the pharma industry," stated Dr. Rummelt. "I am convinced that LEUKOCARE's SPS® formulation technology platform has the potential to improve products regarding thermal stability and shelf life both for new entities as well as for life cycle products and biosimilars."
LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS®) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS® technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS® also protect proteins in biologically functionalized combination devices like extracorporeal blood treatments or wound dressings.
LEUKOCARE is a privately owned biotechnology company founded in 2003, and headquartered in Martinsried/Munich, Germany.
Please visit: http://www.leukocare.com
Michael Scholl, CEO
SOURCE LEUKOCARE AG